Singapore Markets closed

SomaLogic, Inc. (SLGC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.5500+0.1300 (+5.37%)
At close: 04:00PM EDT
2.5500 0.00 (0.00%)
After hours: 04:53PM EDT

SomaLogic, Inc.

2945 Wilderness Place
Boulder, CO 80301
United States
303 625 9000

IndustryHealth Information Services
Full-time employees320

Key executives

NameTitlePayExercisedYear born
Mr. Troy M. Cox M.B.A.Exec. Chairman14kN/A1964
Dr. Roy Smythe M.D.CEO & Director1.27MN/A1962
Mr. Shaun M. BlakemanChief Financial Officer316.49kN/A1978
Dr. Jason Cleveland Ph.D.Chief Technology OfficerN/AN/AN/A
Dr. Nebojsa Janjic Ph.D.Chief Science OfficerN/AN/A1961
Mr. Ruben Gutierrez J.D.Gen. CounselN/AN/A1975
Ms. Alison Marie RoelkeSr. VP of People & CultureN/AN/A1974
Dr. Stephen A. Williams BS, MB, Ph.D.Chief Medical OfficerN/AN/A1960
Mr. Todd JohnsonExec. VP of Diagnostics Bus. UnitN/AN/AN/A
Mr. Adam TaichExec. VP of Life Sciences Bus. UnitN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Corporate governance

SomaLogic, Inc.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.